Nanomaterials evoke pyroptosis boosting cancer immunotherapy.
10.1016/j.apsb.2024.11.011
- Author:
Zhenhua LI
1
;
Ziyue XI
1
;
Chuanyong FAN
1
;
Xinran XI
1
;
Yao ZHOU
1
;
Ming ZHAO
1
;
Lu XU
1
Author Information
1. Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
- Publication Type:Review
- Keywords:
Cancer immunotherapy;
Gasdermin family;
Immunosuppressive tumor microenvironment;
Induction;
Mechanism;
Nanomaterials;
Programmed cell death;
Pyroptosis
- From:
Acta Pharmaceutica Sinica B
2025;15(2):852-875
- CountryChina
- Language:English
-
Abstract:
Cancer immunotherapy is currently a very promising therapeutic strategy for treating tumors. However, its effectiveness is restricted by insufficient antigenicity and an immunosuppressive tumor microenvironment (ITME). Pyroptosis, a unique form of programmed cell death (PCD), causes cells to swell and rupture, releasing pro-inflammatory factors that can enhance immunogenicity and remodel the ITME. Nanomaterials, with their distinct advantages and different techniques, are increasingly popular, and nanomaterial-based delivery systems demonstrate significant potential to potentiate, enable, and augment pyroptosis. This review summarizes and discusses the emerging field of nanomaterials-induced pyroptosis, focusing on the mechanisms of nanomaterials-induced pyroptosis pathways and strategies to activate or enhance specific pyroptosis. Additionally, we provide perspectives on the development of this field, aiming to accelerate its further clinical transition.
